D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Nvidia is making a bold move to change how people use artificial intelligence in everyday life. At its 2026 GTC conference, Nvidia shared a clear message: the future of AI is not just about powerful machines, but about smart agents that can work alongside humans. CEO Jensen Huang explained that the company expects over a trillion dollars in demand for its AI systems by 2027. This huge figure shows how quickly artificial intelligence is growing and how important it is becoming in different industries. According to him, AI is entering a new phase where it will be used more in real-life situations, not just in research or experiments. This shift is being compared to major changes in technology history, such as the rise of personal computers, the internet, and mobile devices. Nvidia believes AI agents could lead to the creation of new companies and transform how work is done across the world. By handling repetitive tasks, these agents could allow people to focus on more important and creative work. At the same time, Nvidia recognizes the risks that come with more powerful AI. Issues like privacy, security, and trust are becoming more important. The company is working to include safeguards to ensure that AI systems are safe and reliable. In the end, Nvidia’s goal is clear. It wants to make AI agents a normal part of daily life. If successful, this shift could change how people work, communicate, and solve problems in the future. As AI agents make their way into the mainstream, some companies like D-Wave Quantum Inc. (NYSE: QBTS) are busy advancing quantum computing as another frontier that is poised to revolutionize all industries. 

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $16.31, up 3.6872%, on 20,797,470 volume. The average volume for the last 3 months is 23,766,583 and the stock's 52-week low/high is $5.77/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Nvidia Moves to Make AI Agents Go Mainstream
• US Military Admits it is Using AI in Attacks Against Iran
• Study Finds AI Tools Trigger "Brain Fry" in Employees Using Them

Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

• Safe Pro recently announced that it has completed the company’s participation in a recent U.S. Army event where soldiers used Safe Pro’s AI tools in real-world operational environments.
• Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”) drone imagery analysis platform was used by soldiers to identify ground-based threats during day and night exercises.
• The threat data collected was also used by the company’s edge-based Navigation, Observation & Detection Engine (“NODE”) to create 2D/3D terrain maps and digital surface models to inform route and mission planning.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-powered defense, security, and situational awareness solutions, recently announced that the company has completed its participation in the U.S. Army Transforming in Contact (“TiC”) 2.0 Autonomous Breach (https://ibn.fm/Tndrj) event.

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Monday's trading session at $4.52, up 5.3613%, on 195,030 volume. The average volume for the last 3 months is 526,722 and the stock's 52-week low/high is $1.47/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - Safe Pro Group Inc. (NASDAQ: SPAI) Successfully Uses the Company’s AI Tools in Real-World Operational Environments at Recent U.S. Army Event
• Safe Pro Group Inc. (NASDAQ: SPAI) Delivers Critical Security and Defense Solutions to Governments and Organizations
• TinyGemsBreaks - Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update

OptimumBank Holdings Inc. (NYSE American: OPHC)

The QualityStocks Daily Newsletter would like to spotlight OptimumBank Holdings Inc. (NYSE American: OPHC).

OptimumBank Holdings (NYSE American: OPHC) announced it has been ranked No. 49 in the S&P Global Market Intelligence 2025 Top 100 Best-Performing U.S. Community Banks under $3 billion in assets, placing it among the top 1.4% of 3,465 eligible institutions and as the only Florida-based bank included in the ranking. The recognition, based on metrics including profitability, growth, efficiency, asset quality and capitalization, reflects the bank’s strong financial performance and disciplined approach, with management also invited to share insights as one of two institutions selected for a national S&P webinar on top-performing banks.

To view the full press release, visit https://ibn.fm/JdpIv

OptimumBank Holdings Inc. (NYSE American: OPHC) is a single bank holding company that owns 100% of OptimumBank, a community bank headquartered in Fort Lauderdale, Florida. OptimumBank offers relationship-driven banking available in person, by phone, and online, serving both local and international clients by offering an alternative to the high fees and impersonal service of larger institutions. Its expertise in real estate and commercial lending has made it a preferred partner for borrowers seeking knowledgeable, accessible financial support.

Driven by disciplined execution and a commitment to local relationships, OptimumBank has experienced substantial organic growth, positioning itself as one of the fastest-growing community banks in the region. The company has surpassed $1 billion in total assets and remains focused on scaling efficiently, maintaining sound credit quality, and delivering strong returns for shareholders.

Looking ahead, the bank is embracing technology modernization while remaining grounded in the principles of relationship-based banking. A new open-architecture core platform, targeted loan expansion, and sustained deposit growth are key pillars of its forward strategy.

Products

OptimumBank offers a full suite of business and personal banking solutions, including Business Banking, Business Lending, SBA Lending Solutions, Treasury Management, and Personal Banking. Its lending focus includes commercial real estate, multifamily, construction, residential, and consumer loans.

The bank achieved Preferred Lender status with the Small Business Administration in just over two years—an uncommon accomplishment—and rapidly scaled its SBA lending operations from zero in record time. Its treasury services and deposit products are supported by a stable core funding base, with a growing percentage of noninterest-bearing demand deposits.

In late 2025, OptimumBank is rolling out a next-generation core banking platform with API-based architecture, enabling paperless processing, streamlined onboarding, and enhanced treasury management tools.

OptimumBank is deeply engaged in the community, providing support to organizations such as Habitat for Humanity of Broward, along with schools, synagogues, and many other nonprofits that are important to its customers and neighbors.

Market Opportunity

The U.S. community banking sector represents a multi-trillion-dollar opportunity, especially in underserved regions where local institutions continue to consolidate. South Florida’s real estate market and growing population create robust demand for personalized commercial lending, construction loans, and deposit services.

According to Mordor Intelligence, the U.S. commercial banking market is expected to grow from $732.5 billion in 2025 to $915.45 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.56%. Within this landscape, OptimumBank is well-positioned to benefit from regional consolidation and rising customer dissatisfaction with national banks.

OptimumBank’s continued investments in talent, technology, and compliance infrastructure ensure scalability as it targets its next major milestone: becoming a top 200 publicly traded bank in the United States. The bank has maintained a track record of net recoveries in recent years, with no loan losses in over seven years and no defaults in its current loan portfolio. In addition, OptimumBank has near-zero exposure to long-dated, low-yield bonds, avoiding the balance sheet drag that has pressured many regional peers.

Leadership Team

Moishe Gubin, Chairman of OptimumBank Holdings, has been a director since 2010. He is also the CEO of Strawberry Fields REIT and previously served as CFO of Infinity Healthcare Management. Gubin is a licensed CPA in New York and the founder of the Midwest Torah Center.

Timothy Terry, President and CEO, has led OptimumBank since 2013 and has over 35 years of banking experience. He previously held senior roles at Enterprise Bank of Florida and other financial institutions, with a background in lending, branch administration, and sales.

Elliot Nunez, EVP and CFO, joined the bank in 2020. He previously served as CFO for Brickell Bank and Mellon United National Bank and worked at KPMG. Nunez is a licensed CPA and Chartered Global Management Accountant.

OptimumBank Holdings Inc. (NYSE American: OPHC), closed Monday's trading session at $5.4, up 5.8824%, on 7,996 volume. The average volume for the last 3 months is 33,138 and the stock's 52-week low/high is $3.53/$5.59.

Recent News

• OptimumBank Holdings Inc. (NYSE American: OPHC) - InvestorNewsBreaks – OptimumBank Holdings, Inc. (NYSE American: OPHC) Ranked No. 49 Among Top 100 U.S. Community Banks By S&P Global
• NetworkNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) Forms OptimumFunding To Launch HUD And FHA Lending Platform
• InvestorNewsBreaks - OptimumBank Holdings, Inc. (NYSE American: OPHC) to Host Feb. 18 Conference Call on Fourth-Quarter and Full-Year 2025 Results

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Men make up just 5% of people getting genetic tests for inherited cancer risks despite dying from cancer at higher rates than women, new research shows. Analysis of more than 224,000 tests revealed men who do get screened face much higher odds of carrying dangerous genetic mutations, with positive results hitting 14% versus 8% for women. The gap represents a major blind spot in cancer prevention. Genetic screening spots inherited vulnerabilities to breast, ovarian, prostate, and colon cancers, letting doctors track high-risk patients and step in early. Women benefit from widespread protocols urging doctors to evaluate hereditary breast and ovarian cancer factors during routine care. Similar systems cover other inherited cancer syndromes in women. Men largely miss out on these frameworks. Scientists urge building better risk tools focused on men, finding what blocks genetic counseling and preventive care access, and weaving hereditary cancer screening into standard primary care for male patients. The analysis covered a large U.S. dataset but faced limits including possible memory errors in family health histories and information from only one commercial lab. Bridging this divide could boost cancer survival by catching disease earlier. Men currently get tested late in illness rather than beforehand, losing chances to detect cancer early or stop it entirely through monitoring and risk-cutting steps. As entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) hit their milestones in efforts to commercialize novel therapies indicated for various malignancies, it would be of great help if individuals who are at a higher risk of developing these cancers are identified early and tracked so that these new treatments can be administered during the early stages of the disease. This will increase the odds of successful treatment. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $2.515, up 9.8253%, on 24,210 volume. The average volume for the last 3 months is 33,082 and the stock's 52-week low/high is $2.0573/$45.8388.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Fewer Men Undergo Cancer Screening, Study Shows
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion
• Researchers Trace Differing Pediatric Brain Tumors to Common Source

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

• The company has introduced a Self-Service Mortgage Experience (“SSME”) allowing borrowers to review loan customized scenarios and lock rates online without speaking to a loan officer.
• The feature provides a 24/7 digital mortgage pathway, reflecting growing demand for self-directed financial services among Millennials and Gen Z.
• Beeline’s AI-powered platform processes applications in seconds and presents personalized mortgage rate options rather than static rate quotes.
• The company’s broader digital infrastructure enables loan closings in 14–21 days, significantly faster than the traditional mortgage timeline.
• The platform targets two major demographic opportunities: younger homebuyers an investors seeking entry into property markets, plus older homeowners accessing home equity.

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform redefining the path to homeownership, announced the launch of a new automated lending pathway designed to streamline the home financing process. The company recently introduced its Self-Service Mortgage Experience (“SSME”), a platform feature that allows borrowers to explore customized loan options, model mortgage scenarios and lock interest rates entirely online. According to a company announcement, the first phase of the feature launched on March 11 and is currently available to roughly half of conventional mortgage applicants using Beeline’s platform (https://ibn.fm/ekxEb).

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Monday's trading session at $2.34, up 1.7391%, on 515,568 volume. The average volume for the last 3 months is 637,461 and the stock's 52-week low/high is $0.6202/$4.65.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - Beeline Holdings Inc. (NASDAQ: BLNE) Launches Self-Service Mortgage Platform to Offer Greater Flexibility and Control to Borrowers
• Beeline Holdings Inc. (NASDAQ: BLNE) Partners with TYTL Corp on Tokenized Fractional Real Estate Model
• TechMediaBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Partners with TYTL to Scale Tokenized Residential Real Estate Equity Platform

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), supporting HyBryte(TM) potential as a therapeutic option for CTCL.

To view the full press release, visit https://ibn.fm/5r9iP

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while also supporting potential at-home treatment through telehealth-enabled delivery. The company is nearing completion of a confirmatory Phase 3 study for HyBryte(TM), with interim analysis expected in early 2026 and top-line results later in the year, alongside supportive data showing strong patient response rates. Soligenix’s broader strategy leverages regulatory incentives for orphan diseases and more than $60 million in non-dilutive funding to advance multiple pipeline candidates, including potential applications in psoriasis and autoimmune conditions, positioning the company for continued growth in rare disease therapeutics.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Monday's trading session at $1.21, up 0.8333333%, on 60,489 volume. The average volume for the last 3 months is 139,620 and the stock's 52-week low/high is $1.02/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer
• InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
• Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF)

The QualityStocks Daily Newsletter would like to spotlight MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF).

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. 

MAX Power Mining (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) announced the closing of its previously announced private placement, raising approximately C$20.5 million in gross proceeds through the sale of 15,805,624 units at C$1.30 per unit, with Eric Sprott as lead investor and Hampton Securities Limited acting as lead agent and sole bookrunner. The company said proceeds will support ongoing evaluation and development of its Lawson Natural Hydrogen discovery in Saskatchewan, including analytical testing, resource modeling, seismic acquisition and additional drilling, alongside general corporate purposes, as it advances what management believes to be a scalable natural hydrogen opportunity across its extensive land position.

To view the full press release, visit https://ibn.fm/i6DhC

MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) is a Canadian mineral exploration company pioneering the development of natural hydrogen as a potential new primary energy source. As a first mover in this emerging sector, the company has assembled North America’s largest permitted land package targeting naturally occurring, emissions-free hydrogen accumulations in the earth’s subsurface.

MAX Power plans to commence Canada’s first dedicated deep drilling program for natural hydrogen in November 2025, starting on the 200-km-long Genesis Trend in southern Saskatchewan, with the goal of converting a discovery into the world’s first commercial natural hydrogen venture in 2026.

Backed by institutional partnerships and a highly experienced technical team, MAX Power continues to build a globally recognized brand in the natural hydrogen sector. Its massive land package in Saskatchewan currently comprises 1.3 million permitted acres with another 5.7 million acres under application.

Saskatchewan, a jurisdiction recognized for its supportive regulatory environment and clean energy innovation, features North America’s most advanced policy framework for the exploration and development of natural hydrogen. The province is also known for its spectacular resource endowment as the world’s leading potash provider, the top high-grade uranium producer in the world, and Canada’s second-largest oil producer. Saskatchewan is also Canada’s leader in helium production, geothermal energy and carbon capture.

The company’s head offices are in Saskatchewan’s two largest cities, Saskatoon and Regina.

Projects

Natural Hydrogen (Saskatchewan)

MAX Power holds multiple large land packages across Saskatchewan prospective for deposits of natural hydrogen, highlighted by the 200-km-long Genesis Trend and the 75-km-wide Grasslands Project.

Genesis features easy road, rail and power access and a proposed hydrogen hub on its eastern side where there is an abundance of potential end-users for natural hydrogen. Drilling is set to begin in early November 2025 at the Lawson target situated in the heart of Genesis. Canada’s first deep well for natural hydrogen is specifically designed to test a complete five-element hydrogen system interpreted to exist at Lawson: source rocks, migration pathways, reservoirs, seals, and traps. Data from vintage and proprietary 2D seismic, gravity and magnetic surveys, and subsurface mapping, among other geological and geophysical information, support the prospectivity of Lawson which lies adjacent to an extensive regional “Salt Barrier” offering excellent seal and trap conditions.

The Genesis Trend’s scalability is further demonstrated by the recent identification of the Lucky Lake target, approximately 50 km northwest of Lawson and one of at least 20 Lawson “look-a-likes” that is being investigated along the trend. Early interpretation suggests serpentinized rocks and structural features favorable for hydrogen generation exist at Lucky Lake.

At Grasslands, geologists are excited about a broad area in the vicinity of a well (“Climax”) near the U.S. border that was drilled a few years ago and inadvertently resulted in Canada’s first known deep subsurface occurrence of natural hydrogen, associated with a rare rock assemblage geologists refer to as “exotic terrane”. Permits covering an area stretching 75 km east-west and up to 10 km north-south were acquired by MAX Power next to this discovery, amplifying the company’s first-mover advantage. Adjacent to three sides of Grasslands are producing helium wells owned by privately-held North American Helium, demonstrating that this under-explored area of the province is highly prospective for clean gas. Drilling of a target at Grasslands is expected during Q1 2026.

Other MAX Power land packages are Rider 1, 2 and 3 in the southeast part of the province, and Choiceland in the north-central part of the province.

To enhance scientific rigor and accelerate development, MAX Power has established a multi-year strategic collaboration with the Petroleum Technology Research Centre (PTRC), a globally recognized leader in subsurface energy research based in Regina, Saskatchewan. This partnership complements the company’s relocation to Innovation Saskatchewan’s R+T Parks in Saskatoon and Regina, placing its technical and executive teams at the heart of the province’s academic, regulatory, and infrastructure ecosystem.

Critical Minerals

MAX Power’s other key asset is its Wilcox Lithium Project in mining-friendly Cochise County in southeast Arizona where first-ever diamond drilling in late 2023/early 2024 confirmed the discovery of near-surface lithium-rich clays over a broad area of the Willcox Playa. MAX Power’s property occurs within a nearly 4,000-acre corridor adjacent to U.S. Department of Defense land, and benefits from direct access through roads, rail and power infrastructure. The discovery was made just as lithium entered its final price downturn and is now being intensely revisited by the company in light of the turnaround in lithium and an emphasis on critical mineral resource development in the United States under the Trump administration.

Market Opportunity

According to company materials, the global hydrogen market is valued at approximately $250 billion and is expected to surpass $400 billion by 2030. Supporting this outlook, a study published in Science Advances (Dec. 2024) estimates that in-place natural hydrogen resources could meet global net-zero carbon goals for roughly 200 years. Closer to home, a feasibility study by the Transition Accelerator (April 2024) projects that the Regina-Moose Jaw Industrial Corridor (RMJIC) in Saskatchewan could support a C$708 million annual hydrogen market, with province-wide demand reaching as high as C$2.7 billion per year.

These projections underscore a compelling opportunity to establish a new energy economy centered around natural hydrogen—a low-cost, low-emission, and potentially naturally replenishing resource. MAX Power is well-positioned to lead this effort with proximity to infrastructure, favorable geology, and increasing institutional support.

Leadership Team

Mansoor Jan, CEO, brings more than two decades of international experience across mining operations, capital markets, and business development. He has held senior positions at BHP Australia, BHP Chile, and Rio Tinto, where he was responsible for advancing cross-border projects, driving mine optimization, and leading technology delivery across major jurisdictions. Mr. Jan holds a BA and MSc in Economics and a Master of Commerce from the University of New South Wales in Australia.

Neil McMillan, Director and Chair of the Audit Committee, is the former Chairman of the Board of Cameco, the world’s largest publicly traded uranium company. Mr. McMillan served on Cameco’s board for 16 years and is highly regarded within and outside the province for his decades of success there. He previously led Claude Resources as President and CEO, paving the way for its development into Saskatchewan’s only profitable gold miner which was bought out for more than $300 million by Silver Standard Resources in 2014.

Steve Halabura, Chief Geoscientist, has decades of successful experience in the province’s resource sector including a deep understanding of the geological controls on the accumulation of hydrogen, helium, and other industrial gases. He was also instrumental in the early formative stages of the only two Saskatchewan greenfield potash mines to come into existence in the 21st century, these being BHP’s Jansen Project and K+S’s Bethune mine. Jansen is the largest private investment ($14 billion) in Saskatchewan history and is located northeast of MAX Power’s Genesis Trend.

Tom Kishchuk, MAX Power’s Senior Strategic Advisor for Natural Hydrogen Development, is CEO for the Saskatchewan-based Global Institute for Energy, Mines and Society (GIEMS). He has over three decades of technical and business leadership in national and global organizations focused on the energy sector.

MAX Power Mining Corp. (OTC: MAXXF), closed Monday's trading session at $0.94, up 3.4786%, on 141,925 volume. The average volume for the last 3 months is 690,310 and the stock's 52-week low/high is $0.105/$1.3.

Recent News

• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) - InvestorNewsBreaks – MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) Closes C$20.5 Million Private Placement Led by Eric Sprott
• Ann Arbor Moves to Create its Own Renewables Utility
• MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) Initiates Commercial Evaluation of Canada's First Confirmed Subsurface Natural Hydrogen System

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF).

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. 

Nevada Organic Phosphate (CSE: NOP; OTCQB: NOPFF) reported a delay in its planned drilling program at the Murdock Mountain phosphate project due to incomplete environmental pre-clearance surveys required by the Bureau of Land Management and Nevada Department of Wildlife, and has engaged an additional environmental consulting firm to accelerate completion of the work. The company is also finalizing an agreement with a second drilling contractor to mitigate scheduling impacts and enable drilling to commence as soon as regulatory approvals are secured.

To view the full press release, visit https://ibn.fm/sUX2k

Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) is a junior exploration company focused on exploring and advancing an organic sedimentary raw rock phosphate project in northeast Nevada. The company’s business model centers on developing a rare, direct-application phosphate product that aligns with the growing demand for organic agricultural inputs. Its vision is to support the rapidly expanding organic food industry with a clean, reactive, environmentally responsible nutrient source that avoids the contamination issues associated with chemically processed fertilizers.

NOP is advancing the Murdock Mountain Project through disciplined exploration, responsible environmental practices, and strategic planning that positions the company as a future supplier of organic phosphate to key agricultural markets. The company emphasizes transparency, environmental stewardship, and adherence to regulatory standards as it advances its drill program and project development.

By developing a unique phosphate resource in a mining-friendly U.S. jurisdiction with strong infrastructure access, NOP aims to establish itself as a significant participant in the organic fertilizer sector.

The company is headquartered in Vancouver, British Columbia.

The Murdock Mountain Phosphate Project

NOP’s flagship asset is the Murdock Mountain Phosphate Project in Elko County, Nevada, a nearly flat-lying sediment-hosted phosphate system traced historically over 6.6 kilometers and extended through additional applications to more than 30 kilometers. The project’s raw rock phosphate is characterized by high purity, absence of heavy metals, and suitability for direct application without processing, aided by francolite (the most reactive crystallite structure of all P₂O₅ minerals) and oolitic textures that provide optimal surface area for interaction with soil micro-organisms. The product’s purity places it within the rare 5% of global P₂O₅ material pure enough for direct field application.

The Murdock Mountain property spans four Bureau of Land Management (BLM) applications totaling 7,824 acres, with an Exploration Target Mineral Inventory (ETMI) of 10–46 million tonnes in the initial 1,813-acre area and an additional 200–220 million tonnes across three further applications. Historic geologic mapping and recent drilling identify the Upper Phosphatic Zone within the Meade Peak Member as the primary target, with an interval historically ranging from 3.4 to 7.6 meters thick within a 28–40-meter phosphatic sequence.

In 2025, NOP commenced a multi-hole drill program with unrestricted seasonal timing following regulatory updates. Drill holes MM25-1, MM25-2, MM25-3, MM25-4 and MM25-5 all intersected favorable Meade Peak phosphate-bearing stratigraphy precisely where predicted by geological modeling. These intersections ranged from 29.2 to 38 meters (96 to 125 feet), with drilling confirming the interpreted dip and continuity of the target zone. Ongoing step-out drilling continues along the phosphate trend, supported by geological mapping and XRF screening, with assays pending. The project benefits from proximity to Highway SR 30, the hamlet of Montello, and the Southern Pacific rail line, enabling a simple mining concept summarized by: “break it up, dig it up, grind it up, bag it up, and ship it out.”

Market Opportunity

NOP intends to supply organic, direct-application phosphate fertilizer to the rapidly expanding organic food sector in North America. The company cites a $35 billion organic food market, supported by data from the U.S. Department of Agriculture’s Economic Research Service, which estimated an 8.7% annual growth rate between 2021 and 2027.

The shift toward organic and regenerative agriculture is driving demand for reactive, non-acidulated phosphate sources, and NOP notes that American farming practices are increasingly moving toward direct-application phosphate rather than soluble chemical fertilizers. With only 5% of global P₂O₅ pure enough for direct application, the company is targeting a rare, high-value segment of the fertilizer market that does not require competition with conventional chemical fertilizer producers.

Leadership Team

Robin Dow, Chairman & CEO, brings extensive experience as a public venture capital entrepreneur, following prior roles as a retail and institutional broker and researcher at Burns Fry. He has created more than 30 private and public companies across multiple sectors, raised close to $200 million, and built resource operations spanning four continents, 10 countries, four U.S. States, four Canadian provinces, and three Canadian territories.

Eric Szustak, Director, offers over 39 years of financial services, accounting, business development, and marketing experience, supported by senior roles at firms including Midland Walwyn, Merrill Lynch, and BMO Nesbitt Burns. He is the former President and current Chairman of Quinsam Capital Corporation and holds multiple directorships in publicly listed companies.

Garry K. Smith, Director, contributes more than 40 years of exploration management for companies such as Kerr Addison, Teck, Rio Tinto, and Lac Minerals. As a Qualified Person, he specializes in project generation, 43-101 reporting, resource evaluation, geological modeling, and metal ion soil geochemistry, with a strong focus on ethical and environmentally responsible exploration practices.

Paul W. Pitman, P.Geo., Director, is a field hardened veteran with extensive experience in all areas of geological exploration for a number of metals and materials. He has over 55 years’ experience as an exploration geologist. Since 1983, he has acted as a geological consultant to over 70 clients, providing a full range of services (geological, corporate, and administrative). He has served as a Director or Officer (VP or President) of several junior resource companies, including Boreal Agrominerals, a producer off organic fertilizers from igneous rock in Northern Ontario. He is semi-retired but directs his geological expertise as an advisor to several fertilizer companies.

Nevada Organic Phosphate Inc. (OTCQB: NOPFF), closed Monday's trading session at $0.0938, up 3.6178%, on 3,789 volume. The average volume for the last 3 months is 884,290 and the stock's 52-week low/high is $0.0334/$0.3212.

Recent News

• Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) - InvestorNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Provides Update On Murdock Mountain Drilling Timeline
• Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) Eyes Scalable Supply of Organic Fertilizer to Support Growth in Organic Agriculture
• RockBreaks - Nevada Organic Phosphate Inc. (CSE: NOP; OTCQB: NOPFF) Mobilizes Teams to Murdock Mountain for 2026 Field Season

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)

The QualityStocks Daily Newsletter would like to spotlight ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF).

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties, just announced the appointment of Jason Tong as its new CFO
• Mr. Tong will lend his experience spanning more than 15 years, equipping ESGold with the support needed for its next phase of growth
• Tong will be key in driving the company’s financial strategy as it transitions toward becoming a producing gold and silver company

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just announced the appointment of Mr. Jason Tong, CPA, CA, CFA, as the company’s Chief Financial Officer (“CFO”), effective immediately. Mr. Tong takes over from Mr. Tony Giuliano, and will play an integral role as the company transitions from development to production at its flagship Montauban Gold-Silver project (https://ibn.fm/0HcCq).

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) is a fully permitted, pre-production resource company on a clear path to near-term gold and silver production. With established infrastructure in place and a significant gold-silver resource, the company is uniquely positioned to generate near-term cash flow while unlocking the full potential of its Montauban Gold-Silver Project in Quebec—one of the top mining jurisdictions in the world.

ESGold is building a foundation for long-term growth through a dual-track strategy: cash-flow generation from tailings reprocessing to fund district-scale exploration.

The Montauban site, which operated as a mine for over 80 years, is now undergoing its first-ever systematic exploration program to determine just how large the remaining deposit may be. Near-term cash flow from tailings reprocessing will be used to fund exploration, with the goal of increasing the resource base and uncovering new discoveries across the expansive land package.

ESGold is advancing a scalable and replicable clean extraction model that turns legacy mine sites into revenue generating assets while setting a new industry benchmark for sustainable resource recovery.

The recent completion of a C$3.4M financing has enabled ESGold to initiate the final construction phase of its mill circuit—moving the company decisively toward production of gold and silver in Q3 2025.

Montauban Gold-Silver Project: Production Imminent

Located approximately 80 kilometers west of Quebec City, the Montauban Project is a past-producing gold-silver mine with surface and underground mineralization and over 900,000 tonnes of historical tailings. ESGold has invested over C$15 million to date, building out roads, power access, and a 16,000 sq. ft. processing facility. The company recently completed a C$3.4M financing to begin final construction of the mill circuit.

The company is fully permitted to enter into production that is expected to commence in Q3 2025 with a capacity of 500 tonnes per day, scaling to 1,000 tpd. An updated Preliminary Economic Assessment (PEA) is currently underway to reflect all-time high gold prices and the anticipated upside from the near-surface resource.

Parallels Between Broken Hill & Montauban

Broken Hill, discovered in 1883 in Australia, became the world’s largest source of silver, lead, and zinc—producing over $100 billion worth of metals. What made it unique was that the richest mineral zones were hidden deep underground in a twisted, boomerang-like shape, and it took decades to fully understand just how large the deposit really was.

Geologists now believe ESGold’s Montauban Project in Quebec may share similar traits. Like Broken Hill, it contains high-grade silver, lead, and zinc, along with gold—and sits within the same type of geological system known to host large, high-value mineral deposits. The rock formations, mineral assemblages, and structural complexity all suggest that Montauban could be hiding much more than what’s been historically uncovered. Academic studies now support this possible geological parallel, pointing to further evidence suggesting Montauban was formed under similar conditions as Broken Hill.

Exploration Upside

With production on the horizon, ESGold is advancing a major exploration campaign. Montauban has never undergone systematic modern exploration.

The company is currently completing a large-scale Ambient Noise Tomography (ANT) survey—a powerful 3D imaging technology that will define the size, shape, and continuity of the mineralized system. ANT is already showing strong results, with imaging going beyond the original 400m depth target and now expected to exceed 800m. This cutting-edge technology has the potential to reveal the full extent of the anomaly for the first time in Montauban’s 110-year history.

Scalable, Replicable, Clean Mining

Montauban is also part of a broader vision. Across Canada and globally, there are hundreds of orphaned or legacy mine sites that remain unrehabilitated despite containing valuable residual metals in tailings. Quebec alone is home to more than 259 of these sites, highlighting the scale of the opportunity. ESGold is advancing a scalable and replicable clean extraction model that transforms legacy sites into productive assets while setting a new benchmark for sustainable resource recovery.

The company has also performed testing that utilizes Dundee Sustainable Technologies’ CLEVR Process™, a proprietary non-cyanide extraction method that achieved 90.9% gold recovery in lab testing. This clean processing approach remains a valuable and scalable asset supporting ESGold’s near-term production and exploration growth strategy.

As a complement to its core mining operations, ESGold is developing clean technology solutions through a joint venture with DMCMS Inc. This initiative includes a polymer division that manufactures environmentally friendly products such as road stabilizers, dust suppressants, and other industrial blends—expanding the company’s sustainable commercial footprint.

Market Opportunity

ESGold is operating in a unique and specialized segment of the mining industry—reprocessing and revitalizing legacy mine sites. The Montauban Project offers both near-term cash flow and long-term growth potential by converting tailings into revenue while systematically exploring for additional high-value mineral endowments. The company’s established infrastructure, full permitting, and reclamation approvals reduce development risk and enhance execution timelines.

The broader green mining market is projected to reach $15.92 billion by 2030, according to Grand View Research. This growth is being driven by increased demand for responsible extraction methods, ESG-aligned practices, and critical mineral security. With construction underway at its fully permitted Montauban site—and exploration advancing along a Broken Hill-type geological model—ESGold is well positioned to emerge as Canada’s next premier gold and silver producer.

Leadership Team

Paul Mastantuono, Chief Executive Officer and Director, graduated with distinction from the University of Ottawa with a bachelor’s degree in social science, concentrating in criminology. He has extensive experience in the construction and transportation industries and has worked as an independent business consultant for various companies, including DNA Precious Metals Inc.

Brad Kitchen, President and Director, brings over 35 years of experience in investment banking and senior corporate management, primarily with resource-based companies. He has a detailed knowledge of regulatory, security, and tax issues, cross-border financings, and market influences, which he has applied to address business challenges for issuers and investors. Mr. Kitchen was also CEO of Eagle Hill Exploration, the company that generated in only five years the first Bankable Feasibility Study on the Windfall Lake Gold Project that was recently sold by Osisko Mining to Gold Fields for US$1.6 billion.

Andre Gautier, Senior Geologist and Director, brings over 47 years of experience in the Mining Exploration field and has worked in over 35 countries. His work experience includes entities such as: SOQUEM, Falconbridge Ltd., Noramco and Cambior Inc. Mr. Gauthier was president of MaxyGold Corp. (China), INCA Pacific Resources Inc., Lara Exploration Ltd., and Gold Holding Ltd. Mr. Gauthier also served as a Director of Vena Resources Inc., MaxyGold Corp., Lara Exploration Ltd., Western Union Peru, and Gold Holding Ltd., and from March 2015 until 2018, he served as interim Managing Director and CEO of Gold Holding Ltd., headquartered in Dubai (UAE). He has a BSC in Geology Eng. and MSC from UQAC (Chicoutimi, Quebec) and is an active member and leader of many mining and professional organizations (Canada, Peru, UAE, and China).

ESGold Corp. (OTCQB: ESAUF), closed Monday's trading session at $0.388, up 0.165221%, on 64,748 volume. The average volume for the last 3 months is 379,810 and the stock's 52-week low/high is $0.1966/$1.1.

Recent News

• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) - ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Strengthens Its Financial Leadership and Corporate Infrastructure with Appointment of Jason Tong as Chief Financial Officer
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Marks Key Step Defining Montauban's Full Scale with 70 Km2 District-Scale ANT Survey, and Closes C$7.2 Million Offering
• ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Files Amended Document for Brokered LIFE Offering; Engages AXINO Capital for European Marketing Services

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego, highlighting findings on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. The presentation underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.

To view the full press release, visit https://ibn.fm/kZzE3

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Monday's trading session at $0.0377, up 0.1328021%, on 105,002 volume. The average volume for the last 3 months is 426,050 and the stock's 52-week low/high is $0.015/$0.11.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
• BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends
• BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum

DitGold

The QualityStocks Daily Newsletter would like to spotlight DitGold

DitGold (CRYPTO: DITAU) is now listed on CoinGecko, a leading cryptocurrency data platform that provides fundamental analysis of the digital asset market, including tracking of price, volume and market capitalization alongside metrics such as community growth, open-source development, major events and on-chain activity. The listing enhances visibility for DitAu within a widely used analytics ecosystem as the project continues building its blockchain-based data monetization platform.

DitGold (CRYPTO: DITAU) is now listed on Coinranking, an independent cryptocurrency data platform known for its real-time pricing, exchange aggregation and user-focused design, providing increased visibility and access to market data across more than 300 exchanges. Coinranking emphasizes unbiased listings without paid placement, alongside fast, mobile-first functionality and millisecond-level data updates, positioning DitAu within a transparent market data environment as the project continues to build out its blockchain-based ecosystem focused on the tokenization and monetization of data assets.

DitGold is a blockchain-based project built on the thesis that data has emerged as the most valuable commodity of the modern digital economy. Drawing parallels to gold as a historical store of value and oil as the fuel of the industrial age, the project positions data as a limitless, non-depleting asset that underpins technological innovation, economic growth, and societal advancement in the 21st century. DitGold frames data not merely as an input but as a core driver of global wealth creation.

The company’s vision centers on redefining how data is valued, owned, and exchanged in an increasingly interconnected world. DitGold asserts that refined, actionable data possesses exponentially greater economic value than raw information and that blockchain technology can provide the transparency, verification, and trust required to unlock that value at scale. Through decentralization, the project seeks to shift control from centralized data holders toward a distributed, community-driven ecosystem.

DitGold’s mission is to create a decentralized infrastructure that acknowledges, tokenizes, and democratizes the value derived from data assets. Through its native ERC-20 token, DitAu, the project aims to enable governance, incentivization, and participation across a data-centric ecosystem designed to support verification, exchange, and long-term value creation.

Portfolio / Ecosystem

DitGold operates a token-centric ecosystem built on the Ethereum blockchain, with DitAu serving as the decentralized unit of value within the network. The token represents participation in the infrastructure and growth of the DitGold ecosystem, which is designed to function as both a marketplace and an underlying data infrastructure layer.

The project’s roadmap outlines a phased development strategy beginning with token launch, liquidity provisioning on a decentralized exchange, and initial community distribution. Subsequent phases focus on the development of data-to-token protocols, the launch of a DitGold testnet, data verification mechanisms, and audited smart contracts. Later stages include mainnet deployment, staking functionality, tokenized data asset products, and a transition to decentralized governance through a DitAu-holder-led DAO.

Within the ecosystem, DitAu is intended to support governance voting, staking and reward mechanisms, access to premium datasets and analytical tools, and incentives for users who contribute verifiable data. The long-term objective is to enable the exchange, licensing, and monetization of refined data assets within a transparent, blockchain-based framework.

Market Opportunity

DitGold is positioned within the broader blockchain infrastructure market, which underpins secure, transparent, and verifiable digital transactions across data-intensive industries. According to MarketsandMarkets, the global blockchain market is projected to grow from $32.99 billion in 2025 to $393.45 billion by 2030, representing a compound annual growth rate of 64.2% during the forecast period.

Growth in the blockchain market is being driven by increasing demand for secure and transparent transaction systems, particularly in sectors such as retail, supply chain management, and banking, where large volumes of sensitive data and financial exchanges are handled. Blockchain’s ability to provide immutable records and real-time verification is cited as a key factor in reducing fraud and data tampering. DitGold seeks to align with these structural trends by positioning its ecosystem as an infrastructure layer for the verification, tokenization, and exchange of data value within a decentralized environment.

Recent News

• DitGold - InvestorNewsBreaks – DitGold (CRYPTO: DITAU) Listed On Coinranking Expands Visibility Across Independent Crypto Data Platform
• InvestorNewsBreaks – DitGold (CRYPTO: DITAU) Now Featured On CoinGecko Data Platform
• CryptoNewsBreaks - DitGold (CRYPTO: DITAU) Gains Exposure as Coinbase Global Inc. (NASDAQ: COIN) Expands DEX Trading Access

ParaZero Technologies Ltd. (NASDAQ: PRZO)

The QualityStocks Daily Newsletter would like to spotlight ParaZero Technologies Ltd. (NASDAQ: PRZO).

ParaZero Technologies (NASDAQ: PRZO) announced it has entered into a definitive agreement for a registered direct offering with a single institutional investor expected to generate approximately $4 million in gross proceeds through the sale of 5,333,333 ordinary shares (or pre-funded warrants) at $0.75 per share. The company said proceeds will be used for general corporate purposes and working capital, with the transaction expected to close on or about March 24, 2026, and Aegis Capital Corp. acting as exclusive placement agent.

To view the full press release, visit https://ibn.fm/FcD5R

ParaZero Technologies Ltd. (NASDAQ: PRZO) is a defense aerospace company specializing in multi-layered Counter-Unmanned Aircraft System (“Counter-UAS”) technologies engineered to neutralize hostile drones in complex, contested, and urban environments. Founded by aviation and defense technology professionals, the company develops autonomous interception and precision-delivery systems that support military forces, homeland security agencies, and operators of strategic infrastructure. ParaZero’s mission is to provide reliable, practical, and scalable counter-drone capabilities for frontline and fixed-site defense scenarios where rapid, accurate, and low-collateral response is essential.

As drone threats evolve from low-cost commercial platforms to fast, low-signature systems operating in RF-denied conditions, ParaZero focuses on solutions that deliver actionable last-layer defense. Its technologies integrate with existing detection and command systems, allowing operators to respond effectively across military bases, sensitive facilities, border regions, and high-risk operational zones. The company’s defense portfolio continues to expand through field collaboration with Israeli defense authorities and international security organizations seeking capable interception systems.

Building on more than a decade of engineering and operational experience, ParaZero offers autonomous counter-drone and precision-delivery capabilities designed for modern defense requirements.

The company is headquartered in Kfar Saba, Israel.

DefendAir

DefendAir is ParaZero’s multi-layered Counter-UAS system designed to intercept hostile drones with high accuracy and minimal collateral damage. The platform employs patented net-interception technology and supports defense forces protecting bases, critical infrastructure, government facilities, and frontline units. Company-reported demonstrations conducted with Israeli defense and homeland security authorities have shown successful interception across a range of real-time scenarios involving fast, maneuverable, and RF-denied drones.

DefendAir is deployed through three complementary delivery mechanisms that enable flexible interception across dynamic battlefield and fixed-site environments:

• Interception Drone – The airborne configuration places a net-interception pod on an autonomous multirotor, enabling rapid engagement of hostile drones approaching from extended ranges or complex angles. This mobile layer offers adaptable response options where ground-based systems may have limited reach.
• Stationary Turret – The turret provides automated 360-degree perimeter coverage for fixed sites. Using optical detection and autonomous tracking, it identifies and intercepts approaching drones with a non-explosive, low-collateral method suitable for urban or sensitive environments.
• Hand-Held Net Launcher – The hand-held launcher offers infantry and security personnel a lightweight, tactical close-range interception tool. It enables unit-level drone neutralization in environments where jamming or spoofing is ineffective, providing a practical last-line defense option.

Together, these configurations provide flexible interception capabilities for a wide range of defense and security missions.

DropAir

DropAir is ParaZero’s high-accuracy aerial delivery solution engineered for autonomous or remotely controlled missions in complex and hostile environments. The system enables safe, precise delivery of sensitive payloads, including medical supplies, blood transfusions, tactical equipment, and humanitarian aid, without requiring the drone to land or expose ground personnel to risk. Its HALO-style late parachute deployment minimizes drift and lowers detectability, supporting both multirotor and fixed-wing UAVs.

DropAir has demonstrated operational effectiveness in collaboration with the Israeli Ministry of Defense and the Israel Defense Force Medical Corps, including a breakthrough field trial in which blood transfusions dropped from 200 meters were recovered fully intact and suitable for human use.

The system’s modular pod design secures a variety of payloads and is adaptable to a wide range of UAV platforms, with carrying capacities of 5, 10, or 20 kilograms depending on drone capability. Built for rapid deployment and all-weather performance, DropAir provides reliable resupply options for defense, disaster response, and remote operations where conventional logistics cannot safely reach.

Market Opportunity

ParaZero operates within rapidly expanding segments of the global unmanned systems and defense markets. According to Fortune Business Insights, the anti-drone (counter-UAS) market was valued at $2.4 billion in 2024 and is projected to grow from $3.1 billion in 2025 to $12.24 billion by 2032, reflecting a compound annual growth rate of 21.62%. This expansion is driven by the increasing use of drones in modern conflicts, the emergence of new threat types such as RF-denied and fiber-optic-guided drones, and the need to protect critical infrastructure, military bases, and sensitive facilities.

The precision airdrop category is also gaining traction as defense forces and emergency agencies seek secure, rapid, and unmanned delivery solutions for time-critical missions. ParaZero’s DropAir program has advanced into Phase II with the Israeli Defense Force Medical Corps, highlighting governmental adoption of autonomous delivery technologies for military and humanitarian use.

Leadership Team

Ariel Alon, Chief Executive Officer, is an experienced executive with a proven track record of leading high-performing business teams across unmanned aircraft systems, finance, high-tech, defense, and government sectors in Israel, the U.S., EMEA, and APAC. Prior to joining ParaZero, he served as Chief Sales Officer of Aerodrome Group and CEO of its subsidiary, Aerodrome LTD. His earlier roles include vice president of sales and general manager for Israel at Voyager Labs, Israeli country manager for Atos, and business development positions at companies including Elbit Systems and Rafael Advanced Defense Systems. Mr. Alon holds a B.A. in business administration and an M.B.A. in finance and marketing from the Ruppin Academic Center in Israel.

Regev Livne, Chief Financial Officer, previously served as CFO of Votiro, where he raised capital and supported the company’s expansion into North America and Asia. His earlier experience includes serving as CFO of SCR Engineers Ltd., along with finance roles at 3M Attenti and Dmatek Ltd. Mr. Livne began his career as a senior accountant at PwC Israel, auditing both public and private companies. He is a Certified Public Accountant in Israel and holds a master’s degree in finance and management and a B.A. in business administration and accounting from the Israeli College of Management.

Alon Yasovsky, Vice President of R&D, is an engineering leader with more than 20 years of experience across electro-optics, machine vision, embedded systems, and advanced technology development. He previously worked in Samsung Electronics Israel’s Open Innovation group and evaluated R&D investments for the Israeli Innovation Authority. Earlier in his career, he held engineering and leadership roles at SensoGenic, Kornit Digital, Intel, Apple, PrimeSense, and Elbit Systems. Mr. Yasovsky holds a B.Sc. in electrical and electronic engineering from Tel Aviv University and completed the U.S.–Israel Innovation Bridge Leadership Executives Program at the University of California, Irvine.

Paid Promotional Disclosure

This press release constitutes a paid promotional communication. The Company has engaged a third-party service provider to provide investor awareness and promotional services, including the dissemination of this press release, and has paid a fee for such services. The Company exercises editorial control over the content of this press release but does not control how, when, or to whom the information is distributed by such third party.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. Investing in securities involves significant risks, and readers are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission available at www.sec.gov before making any investment decision.

ParaZero Technologies Ltd. (NASDAQ: PRZO), closed Monday's trading session at $0.87, off by 18.6916%, on 2,461,707 volume. The average volume for the last 3 months is 1,394,595 and the stock's 52-week low/high is $0.5255/$2.145.

Recent News

• ParaZero Technologies Ltd. (NASDAQ: PRZO) - InvestorNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Prices $4 Million Registered Direct Offering
• DefenseNewsBreaks - ParaZero Technologies Ltd. (NASDAQ: PRZO) Signs Strategic Cooperation Agreement With BonV Aero To Expand Counter-UAS Presence In India
• TechMediaBreaks - ParaZero Technologies Ltd. (NASDAQ: PRZO) Appoints Bat-Sheva Noy as Vice President of Global Sales